三亿体育

Chongqing Pharscin Pharmaceutical Co., Ltd. (stock abbreviation: Pharscin Pharma, stock code: 002907) is a key national high-tech enterprise with an integration of the research and development, production and sales of drugs. Its headquarter and research center are based in Liangjiang new area of Chongqing city and its production center is located in Rongchang High-tech Zone, Chongqing.

Pharscin Pharma owns Chongqing Pharscin Medicine Co., LTD., Chongqing Pharscin Pharmacy Retail Chain Co., Ltd., Chongqing Pharscin Biotech Co., LTD. and Pharscin US Inc.

Guided by the technology-led, innovation-driven, inheriting the essence, keeping integrity and innovation principle, the Pharscin Pharma stays committed to manufacturing high quality products with special, sophisticated, unique and innovative features. At present, it has 70 drug varieties, including Chinese patent medicine, APIs and preparations. Among them 51 drugs are in the catalog of National Medical Insurance, development of 46 items of national drug standards, 64 drugs have patents.

Pharscin Pharma has undertaken national, provincial and ministerial scientific and technological research and development projects as many as 119, including the National "Eleventh Five-Year" Major New Drug Development, the National "Twelfth Five-Year" Major New Drug Development, the National 863 High-Tech Plan, the National Torch Plan and among others, giving all it has to better human life and health.

Pharscin Pharma introduced the chief scientific officer of innovative drug R&D from the United States, built an internal R&D system and created a R&D talent team, focusing on the research and development of innovative anti-cancer drugs and tumor immunological drugs, and has established 3 internatianal cutting-edge innovative drug R&D technology platforms: 1. Cancer driver gene target biological screening platform besed on functional genomics; 2. Medicinal chemistry design and synthesis platform for the molecular biological structure of new targets; 3. Drug metabolism and pharmacokinetics (DMPK) research and test platform. The company has initiated 3 first-in-class innovative drug development projects and made good progress; it has cooperated with the professor of bioinformatics at Mount Sinai School of Medicine in New York, the professor of cancer biology at Indiana University, and the academician of the University of British Columbia in Canada. Living in the strategic opportunity of the construction of the dual-city economic circle in the Chengdu-Chongqing reqion, Pharscin Pharma cooperated with the State Key Laboratory of Biotherapy of Sichuan University to invest in the establishment of Chengdu Origiant Pharma to develop innovative drugs for tumor immunity and achieve a breakthrough in innovative drugs from 0 to 1.

Pharscin Pharma regards drug quality as the life of the company, and has established a quality management system that meets international advanced standards and covers all factors affecting drug quality, and carries out high-standard dynamic management of drug quality risks in an all-round way. The company's products have consistently maintained four 100% pass rates of factory finished product inspection, random inspection by the drug authority, national evaluative random inspection, and market random inspection. Pharscin Pharma has successively won the Chongqing Mayor Quality Award, China's Pharmaceutical Industry Excellent Quality Management Unit, National Pharmaceutical Industry Excellent QC Activity Team, and the Ministry of Health Health Newspater "Safe and Reliable Medicines ", so it enjoys a high reputation among consumers and medical workers.

Pharscin Pharma has always adhered to professional academic promotion, and conveyed leading, accurate and up-to-date information and services to medical workers. At present, the academic network has covered 31 provinces, municipalities and autonomous regions across the country, and has established Pharscin US Inc. in the United States. It marks that Pharscin Pharma is making great strides towards the international market.

Pharscin Pharma actively fulfills its social responsibilities, adopts the "company + farmer" model, establishes standardized planting bases of Chinese medicinal materials in Rongchang, Xiushan, Wanzhou of Chongqing, participates in targeted poverty alleviation, and drives local farmers to increase income and become rich. Pharscin Pharma donates to the frontline of epidemic areas such as Wuhan Medicines and medical protective materials exceeded 2 million yuan; 5.12 Wenchuan earthquake relief, 4.20 Ya'an earthquake...... Every public welfare scene, Pharscin Pharma’s people are active. For these reasons, Pharscin Pharma has successively won honors such as "Caring Unit", Chongqing Advanced Private Enterprise in Fighting the COVID-19, and Advanced Private Enterprise of "Ten Thousand Enterprises Helping Ten Thousand Villages" Targeted Poverty Alleviation Action.

Pharscin Pharma regards talents as the first resource for enterprise development, and currently employs more than 1,300 people. The company has always adhered to the talent strategy of "people-oriented and achieving employees", carried out all-round training for employees, and introduced a number of welfare insurance systems to provide employees with sustainable development space. At the same time, the company pays attention to creating a corporate culture atmosphere of "Pharscin Pharma is my home", improving employees' sense of belonging and initiative, and achieving employee happiness.

Pharscin Pharma takes "developing quality medicine, healthying mankind, accomplishing employees" as the company mission, upholds "honesty, diligence, gratitude, studying, teamwork and innovation” as the company value, are striving for the Pharscin Pharma’s dream of "To be a world-class pharmaceutical company, so that there are no intractable diseases in the world" in a steady pace, contributing to the construction of the two-city economic circle in the Chengdu-Chongqing region, and contributing to the realization of the Chinese dream of the great rejuvenation of the Chinese nation.